• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec12
Wedbush Analyst Maintains Buy Rating on BioCryst with $21 Price Target
13:38
Dec3
BioCryst Pharmaceuticals Plans to Merge with Astria Therapeutics
12:00
Nov12
BioCryst Pharmaceuticals to Acquire Astria Therapeutics for $8.55 per Share and 0.59 Shares
13:03
Nov8
HC Wainwright Raises BioCryst Pharmaceuticals' EPS Forecast for FY2025
14:20
Nov6
BioCryst Pharmaceuticals Releases ORLADEYO® Clinical Trial Data
13:00
Nov3
Belanger Maintains BioCryst's Stock Rating
21:56

Schedules & Filings

Schedules
Filings
Nov3
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 159.4 M, Net Income 12.9 M, EPS 0.06

Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 163.35 M, Net Income 5.085 M, EPS 0.02

May5
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 145.53 M, Net Income 32 K, EPS 0.0001

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More